Year: 2025

Aspo PlcStock Exchange ReleaseJanuary 10, 2025 at 2:00 pm Charges brought against Aspo board member in the matter concerning Ramirent Plc have been withdrawn Aspo Plc has been informed that the public prosecutor has withdrawn the charges brought against former Ramirent Plc CEO Tapio Kolunsarka for suspected securities market disclosure offence. Aspo Plc has not been a party to the case, and the matter has not had any impact on Tapio Kolunsarka’s work on the Board. Aspo Plc  Rolf Jansson CEO   Further information, please contact:  Rolf Jansson, CEO, tel. +358 40 0600 264, rolf.jansson@aspo.com   Distribution: Nasdaq Helsinki Key Media  www.aspo.com  Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their...

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides a clinical development and operational update for 2025. “The important work we conducted throughout 2024 has led us into what we believe is an exciting 2025 as we build off positive data generated in oncology and the addition of a new application for BP1001-A in the treatment of obesity for Type 2 Diabetes. This new application compels us to advance these studies as quickly as possible and to file for regulatory designations...

TORONTO, Jan. 10, 2025 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a technology company enabling the global mining industry to monetize valuable metals contained in mine waste and tailings, reduce environmental liabilities and improve social and environmental outcomes, is pleased to announce that it has increased the size of its previously announced non-brokered private placement financing due to increased investor interest, to raise up to CAD $4,000,000 of gross proceeds, consisting of up to 4,000 units (the “Units”) issued at a price of CAD$1,000 per Unit. Each Unit will consist of CAD$1,000 principal amount of unsecured convertible notes and 11,112 common share purchase warrants of the Company. All other terms of the Financing remain as set out in the Company’s...

HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) — Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) announced today that management will participate in a fireside chat hosted by Jeff Grampp, Senior Analyst at Alliance Global Partners on January 23, 2025. Details of the call are provided below. Date and Time: Thursday, January 23 at 12:00 p.m. ET Webcast: https://us02web.zoom.us/webinar/register/WN__puxX4MVSdaiAls6CkBOow A replay of the fireside chat will be available for at least 30 days following the event on the investor relations section of the Company’s website. About Amplify Energy Amplify Energy Corp. is an independent oil and natural gas company engaged in the acquisition, development, exploitation and production of oil and natural gas properties. Amplify’s operations are focused in Oklahoma, the Rockies (Bairoil),...

Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health Safety and Efficacy Data Support Initiation of Phase 3 Clinical Trial Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. “These exciting results...

Oslo, 10 January 2025 – PCI Biotech (OSE: PCIB), today announced that the Board of Directors has granted share options to Morten Luhr who has been promoted to Chief Scientific Officer (CSO) from January 2025. Anders Høgset, former CSO, will commence as Scientific Advisor in a 20% position. In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 75,000 share options to a key employee. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech’s choice), at a strike price of NOK 1.35, equal to the volume weighted average share price (VWAP) for the last 5 days of trade prior to the grant date. The...